Late-Breaking Science

Scientific Sessions 2018

November 10–12

Chicago, Illinois

Click on any Late Breaking session title below to see the lineup in the online Program Planner.

LBS.01 - Answers to Critical Questions in Cardiovascular Prevention

When: Saturday, November 10, 2018, 2:00 p.m.–3:15 p.m.
Where: Main Event I

    The VITamin D and OmegA-3 TriaL: Principal Results for Vitamin D and Omega-3 Fatty Acid Supplementation in the Primary Prevention of Cardiovascular Disease and Cancer
    The Primary Results of the REDUCE-IT Trial
    Ezetimibe in Prevention of Cerebro- and Cardiovascular Events in Middle- to High-risk, Elderly (75 Years Old or Over) Patients With Elevated LDL-cholesterol: A Multicenter, Randomized, Controlled, Open-label Trial
  • Cost-Effectiveness of Alirocumab Based on Evidence from a Large Multinational Outcome Trial: the ODYSSEY OUTCOMES Economics Study

LBS.02 - Novel Approaches to CV Prevention

When: Saturday, November 10, 2018, 3:45 p.m.–5:00 p.m.
Where: Main Event I

    The Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial
  • CIRT
    The Cardiovascular Inflammation Reduction Trial (CIRT): Low Dose Methotrexate for the Prevention of Atherosclerotic Event
    Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients with Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial
  • Yoga-CaRe
    Effectiveness Of A Yoga-based Cardiac Rehabilitation (yoga-care) Program: A Multi-centre Randomised Controlled Trial Of 4,014 Patients With Acute Myocardial Infarction From India

LBS.03 - Harnessing Technology and Improving Systems for Global Health

When: Saturday, November 10, 2018, 5:30 p.m.–6:45 p.m.
Where: Main Event II (s100)

    Effects of a Multifaceted Intervention to Narrow the Evidence-Based Gap in the Treatment of High Cardiovascular Risk Patients: the BRIDGE CV Prevention Cluster Randomized Trial
  • BRIDGE Stroke
    An International Cluster Randomized Quality-improvement Trial to Increase the Adherence to Evidence-based Therapies for Acute Ischemic Stroke and Transient Ischemic Attack Patients - the Bridge Stroke Trial
    Alert-Based Computerized Decision Support to Increase Anticoagulation Prescription Prevents Stroke and Myocardial Infarction in High-Risk Hospitalized Patients With Atrial Fibrillation: A Randomized, Controlled Trial
    Efficacy of Electronic Clinical Decision Support in Atrial Fibrillation: Results of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation
  • mWellcare
    Effectiveness of mHealth based Decision Support System for Integrated Management of Chronic Conditions in Primary Care: The mWellcare Trial

LBS.04 - Preserving Brain & Heart in Acute Care Cardiology

When: Sunday, November 11, 2018, 9:00 a.m.–10:15 a.m.
Where: Main Event I

    Pre-hospital Resuscitation Intra-arrest Cooling Effectiveness Survival Study - the Princess Trial
  • Neuroprotect post-CA trial
    Early Goal-directed Hemodynamic Optimization in Comatose Survivors After Out-of-hospital Cardiac Arrest: The Neuroprotect Trial
  • T-TIME
    A Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of Low-Dose Adjunctive Alteplase During Primary PCI (T-TIME)
    Optimal Timing of Intervention in Non St-elevation Acute Coronary Syndromes Without Pretreatment
  • Door to Unload (DTU) Trial
    Mechanically Unloading the Left Ventricular and Delaying Reperfusion in Patients with Anterior ST-segment Elevation Myocardial Infarction: The Door to Unload Pilot Trial

LBS.05 - Hot News in HF

When: November 11, 2018, 10:45 a.m.–12:00 p.m.
Where: Main Event I

  • PIONEER-HF Trial
    Angiotensin Receptor-Neprilysin Inhibition in Patients Hospitalized With Acute Decompensated Heart Failure: Primary Results of the PIONEER-HF Randomized Controlled Trial
    Withdrawal of Pharmacological Heart Failure Therapy in Recovered Dilated Cardiomyopathy - A Randomised Controlled Trial (TRED-HF)
  • Effects of Rivaroxaban on Thrombotic Events in Heart Failure Patients with Coronary Disease and Sinus Rhythm
  • The EMPA-Heart Trial
    EMPA-HEART Cardiolink-6 Trial: A Randomized Trial Evaluating The Effect Of Empagliflozin On Left Ventricular Structure, Function And Biomarkers In People With Type 2 Diabetes (T2D) And Coronary Heart Disease
  • Cardiac Remodeling following Ligation of Arteriovenous Fistula in Stable Renal Transplant Recipients: A Randomised Controlled Study

LBS.06 - Late Breaking Science in Coronary Revascularization

When: Sunday, November 11, 2018, 5:30 p.m.– 6:45 p.m.
Where: Main Event II (s100)

    Endoscopic Vein Harvest for Coronary Bypass Surgery in a Randomized Multicenter Trial With Long-Term Follow-up
  • FREEDOM Follow-On Study
    Long-term Survival following Multivessel Revascularization in Patients with Diabetes: the FREEDOM Follow-On Study
  • TiCAB
    A Randomized, Double-blind Study Of Ticagrelor Versus Aspirin In Patients Undergoing Coronary Bypass Surgery
    Ten-Year Clinical Outcomes After Coronary Drug-Eluting Stents with Biodegradable or Permanent Polymer Coating: Results from the Randomized ISAR-TEST 4 Trial
  • Intramyocardial Injection of Mesenchymal Precursor Cells in Left Ventricular Assist Device Recipients: Impact on Myocardial Recovery and Morbidity